Prolocor is developing a precise diagnostic test utilizing advanced biomarker analysis to assess and manage cardiovascular disease risk. This technology addresses the lack of effective diagnostic tools that can guide individualized therapy for patients suffering from atherosclerotic cardiovascular disease.
Funding
$4.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Atherosclerotic cardiovascular disease is a leading cause of death and disability in the United States, yet current diagnostic tools lack the precision needed to effectively guide individualized therapy for patients. This lack of precision hinders optimal risk assessment and management of cardiovascular disease.
Solution
Prolocor is developing a diagnostic test that utilizes advanced biomarker analysis to provide a more precise method for assessing and managing cardiovascular disease risk. The test aims to address the unmet need for effective diagnostic tools that can guide individualized therapy for patients with atherosclerotic cardiovascular disease. By offering a more precise assessment, Prolocor's technology seeks to empower physicians to make more informed treatment decisions.
Target Audience
The primary audience includes physicians and healthcare providers involved in the diagnosis, treatment, and management of patients with or at risk of developing atherosclerotic cardiovascular disease.
Features
- Advanced biomarker analysis for precise cardiovascular disease risk assessment.
- Designed to guide individualized therapy for patients with atherosclerotic cardiovascular disease.
- Aims to provide doctors with more informed treatment decision-making capabilities.